PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Get Free Report) has received a consensus rating of “Hold” from the fifteen research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $37.2727.
Several equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Tuesday, April 21st. Wall Street Zen upgraded PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Piper Sandler restated an “overweight” rating and set a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a research note on Thursday, April 30th. Truist Financial restated a “hold” rating and set a $25.00 target price (down from $30.00) on shares of PROCEPT BioRobotics in a research note on Thursday, July 2nd. Finally, Evercore assumed coverage on PROCEPT BioRobotics in a research report on Wednesday, June 24th. They set an “outperform” rating and a $30.00 target price on the stock.
View Our Latest Stock Report on PROCEPT BioRobotics
Hedge Funds Weigh In On PROCEPT BioRobotics
PROCEPT BioRobotics Stock Up 1.6%
Shares of PROCEPT BioRobotics stock opened at $21.22 on Tuesday. The firm’s 50 day moving average price is $24.70 and its 200-day moving average price is $26.55. The company has a quick ratio of 5.51, a current ratio of 6.73 and a debt-to-equity ratio of 0.15. PROCEPT BioRobotics has a 52-week low of $19.35 and a 52-week high of $62.17. The company has a market cap of $1.21 billion, a P/E ratio of -11.66 and a beta of 0.87.
PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 27.70% and a negative net margin of 31.82%.The firm had revenue of $83.13 million for the quarter, compared to the consensus estimate of $80.52 million. During the same quarter last year, the firm earned ($0.45) EPS. The company’s revenue was up 20.1% compared to the same quarter last year. On average, sell-side analysts predict that PROCEPT BioRobotics will post -1.53 EPS for the current fiscal year.
About PROCEPT BioRobotics
PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.
The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.
Read More
- Five stocks we like better than PROCEPT BioRobotics
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
